Chinese Sinovac vaccine has just 50% efficacy rate

Brazil has released very disappointing new data on final trials of a Covid-19 vaccine Sinovac from China. As per Brazil study, 50.4% efficacy against coronavirus was found in Brail’s drug trials. 

Sinovac done it’s trials in different nations like in Saudi Arabia and Brazil. 50.4% efficacy is well below the 78% efficacy rate that the institute announced a week before. As per World Health Organization (WHO) efficacy rate for all vaccines require 50%.

Sao Paulo based Butantan Institute said the lower efficacy rate was caused by the inclusion of Covid-19 patients with very light symptoms. Medical experts and WHO officials were criticized conflicting data about the Sinovac jab. They suspect it was confusing, especially when compared with the results from trials elsewhere. One vaccine has different efficacy results in different countries. But it is proved in case of Sinovac vaccine. In Indonesia, drug trials found CoronaVac to be 65.5% effective, while efficacy results from Turkey found to be 91.25%.

Sinovac Pharma officials have not made any comment of Brazil study. Brazil has aimed to roll out its vaccine campaign in January. Relatively low efficacy indicating that even with the vaccine it will take longer for Brazil to curb pandemic. But they said nothing at the time about a group of “very mild” infections among those who had received the vaccine but did not require clinical assistance. Several countries, including Indonesia, Turkey and Singapore, have placed orders for the Sinovac vaccine.